Real-world outcomes in patients with chronic obstructive pulmonary disease initiating long-acting mono bronchodilator therapy.
Lindsay G S BengtsonMichael DePietroJeffrey McPheetersKathleen M FoxPublished in: Therapeutic advances in respiratory disease (2019)
Patients initiating long-acting mono bronchodilator therapy had high rates of medication discontinuation or augmentation. Patients used more rescue medications and experienced significantly more COPD exacerbations with higher healthcare costs compared with baseline. Further research is warranted to determine whether more aggressive initial therapy would result in symptom improvement.
Keyphrases
- healthcare
- end stage renal disease
- ejection fraction
- chronic obstructive pulmonary disease
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- cystic fibrosis
- emergency department
- metabolic syndrome
- patient reported outcomes
- mesenchymal stem cells
- air pollution
- adipose tissue
- skeletal muscle
- health insurance
- soft tissue
- health information